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Abstract. The effects of the EGFr inhibitor Iressa on development of urinary bladder cancers induced by hydroxybutyl(butyl)
nitrosamine (OH-BBN) in rats were examined. Iressa treatment
(4.5 or 1.5 mg/kg BW/day) beginning one week after the last
dose of OH-BBN decreased the occurrence of large (>200 mg)
bladder cancers at termination of the study by 75 and 52%,
respectively. Treatment with Iressa (10 mg/kg BW/day) beginning one week or three months (delayed initiation) after the last
dose of OH-BBN also significantly increased tumor latency
and decreased the incidence of palpable bladder cancers. In the
delayed initiation study, microscopic cancers already existed
when treatment was initiated; implying that the effects of
Iressa occur late in tumor progression. Potential pharmacodynamics and/or efficacy biomarkers modulated by short-term
exposure (5 day) to Iressa (10 mg/kg BW/day) were determined
in palpable bladder lesions by using three different approaches:
i) direct immunohistochemical examination of EGFr related
proteins; which showed that phosphorylated EGFr, AKT
and ERK were significantly decreased; ii) measurement of
protein expression by two dimensional gel electrophoresis and
tandem mass spectrometry. This showed that the Annexin
A2, MAP kinase kinase and nucleolin (all proteins associated
with the VEGF pathway) were decreased in treated tumors;
and iii) measurement of gene expression determined in gene
microarrays demonstrated that numerous pathways were
markedly altered by Iressa treatment. In particular, cell cycle
genes related to the anaphase protein complex (APC) pathway,
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including CDC 20, cyclin B1, BUB1 and both of the Aurora
kinases, were significantly decreased.
Introduction
The OH-BBN induced urinary bladder cancer model has been
used to screen for potential chemopreventive agents (1,2).
The model yields invasive bladder cancers with most tumors
being pathologically classified as transitional cell carcinomas
(TCC). The resulting tumors show various protein changes;
e.g., increased levels of survivin and GST Pi, and decreased
levels of FHIT (3). These changes are often observed in
human bladder tumors as well. More recently, we have examined gene expression in these tumors by microarray analysis,
and have found a wide variety of genes to be overexpressed;
including cyclin D1, PCNA, the calcium binding proteins
S-100 (4,5), Annexin and numerous genes associated with
the EGFr pathway (4). In fact, a recent paper implied that the
tumors which form in the rat urinary bladder cancer model
are similar to invasive bladder cancers in humans when evaluated by gene arrays (5).
Among the genes found to be overexpressed were those
associated with the EGFr pathway. Previous studies in humans
have shown overexpression of phosphorylated EGFr in many
urinary bladder tumors (6,7). These small molecule inhibitors
(Iressa and erlotinib) function as competitive inhibitors of
EGFr autophosphorylation at the AMP binding site and
may indirectly affect downstream activities in the signaling
cascade, including phosphorylation of AKT and ERK (8). We,
therefore, recently tested the ability of the small molecule
EGFr competitive inhibitor Iressa to prevent urinary bladder
tumor formation when administered either immediately
following the last dose of OH-BBN, or 3 months following
the last dose of OH-BBN when microscopic lesions, including
TCC, already existed (1). It was found that Iressa (10 mg/kg
BW/day, by gavage) was highly effective at either time-point;
suggesting that the EGFr inhibitor was effective late during
the cancer progression process. In the present studies, these
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findings were expanded to investigate the chemopreventive
dose response of Iressa in this model, and to examine potential
biomarkers that might give further insight into its mechanism
of action. Also, the studies offer potential pharmacodynamic or
efficacy biomarkers relevant to treatment with EGFr inhibitors
in clinical trials. All biomarkers were examined in rats bearing
large urinary bladder cancers that were treated for 5 days
with Iressa. Three different approaches were employed in the
biomarkers studies: i) specific biomarkers directly associated
with inhibition of EGFr, including phosphorylated EGFr, AKT
and ERK; ii) non-specific proteins whose expressions were
altered as assessed by employing 2-D gel electrophoresis and
tandem mass spectroscopy; and iii) non-specific alterations in
gene expression employing RNA microarray analyses. Gene
changes were examined both for altered expression of specific
pathways, as well as identifying a wider group of genes
whose expression was significantly altered. It was found that
expression of cell cycle related genes were altered, including
various cyclins, BUB1 and both Aurora kinases. These various
modulated biomarkers may serve as pharmacodynamic and/
or efficacy indicators for treatment with this class of agents in
clinical trails.
Materials and methods
For all studies, female Fischer-344 rats were obtained from
Harlan Sprague-Dawley, Inc. (Indianapolis, IN). OH-BBN was
purchased from TCI America (Portland, OR) and administered by gavage (150 mg/dose, 2x/week for 8 weeks) beginning
when the rats were 56 days of age. All animal experiments
were conducted in facilities at the University of Alabama
at Birmingham following the procedures approved by the
Institutional Animal Care and Use Committee. Iressa was
supplied by the National Cancer Institute/Division of Cancer
Prevention Chemical Repository.
Chemopreventive studies. For the dose-dependent study, Iressa
treatment (either 4.5 or 1.5 mg/kg BW/day) was initiated one
week after the final OH-BBN treatment (115 days of age).
Iressa was administered by gavage daily (vehicle was ethanol:
polyethylene glycol 400; 10:90; v/v). Each gavage volume was
0.5 ml. As previously reported (1), treatment with Iressa at a
higher dose (10 mg/kg BW/day) was also given, but was initiated
either 1 week or 3 months after the final OH-BBN treatment
(rats were 195 days of age at time of initial treatment). All
studies were terminated at 8 months after the initial carcinogen
treatment. All bladder cancers were confirmed by histological
evaluation. All rats were weighed 1x/week and palpated for
urinary bladder tumors 2x/week as previously described (1,9).
Rats were sacrificed when they developed a large bladder mass
or at termination of the study. Individual weights of the urinary
bladders plus lesions in each group were compared using
Wilcoxon rank analysis. Differences between the incidence of
large bladder tumors (weight of bladder plus lesions >200 mg)
in the various groups were analyzed by χ2 analysis.
Biomarker studies
Generation of tissues. OH-BBN treated rats were allowed to
develop a palpable lesion and were then treated for 5 days with
Iressa (10 mg/kg BW/day) or with the vehicle. At sacrifice, the

tumor was divided and either snap frozen in liquid nitrogen or
placed in Zamboni's fixative.
Two-dimensional difference gel electrophoresis and image
analysis of bladder cancers. Bladder tumors were prepared
in a sample buffer (30 mM Tris-HCl pH 8.5, 7 M urea, 2 M
thiourea, 4% CHAPS) and labeled with 400 pmol of Cy2, Cy3
or Cy5. Pools were prepared by mixing equal protein amounts
of each sample following labeling. All samples were then
equilibrated into immobilized pH gradient (IPG) strips under
100 V followed by isoelectric focusing using a maximum
of 10,000 focusing volts (Protean IEF cell, Bio-Rad). After
focusing, proteins were reduced with TCEP (10 mM) and alkylated with iodoacetamide (20 mM). The IPG strip was then
layered on 10% polyacrylamide gels followed by SDS-PAGE
separation. Samples were imaged with a Typhoon Imager (GE
Healthcare) using specific excitation/emission wavelengths:
488/520 nm for Cy2, 520/580 nm for Cy3, 620/670 nm for Cy5.
The DeCyder (ver. 6.5) software tools (GE Healthcare) were
used for image analysis. The DIA (differential in-gel analysis)
module was used to align and normalize images within each
gel. Spots with slopes >1.1, areas <100, volumes <10,000 and
peak heights <100 were excluded. The DIA module calculated
abundance ratios using a normalization algorithm that was
applied as previously described (10). For comparative pairwise analyses of gel features across different physical gels,
the DIA data sets were analyzed using the BVA (biological
variation analysis) module. Spot volumes were converted to
ratios of a pooled internal standard. Using the extended data
analysis (EDA) module, a t-test was performed to determine
the statistical significance of ratios for each gel feature.
Protein identification of gel features using tandem mass
spectrometry. Gel features were excised robotically (ProPic,
Genomic Solutions) using a triangulation algorithm implemented with in-house software. The gel pieces were digested
in situ with trypsin (11). Samples were processed and analyzed
using nano-LC-FTMS/MS as previously described (12). The
‘raw’ files were processed using MASCOT Distiller, version
2.1.1.0 (Matrix Science, Oxford, UK) with the following
settings: i) MS processing, 200 data points per Da; no aggregation method; maximum charge state, +8; minimum number of
peaks, 1. ii) MS/MS processing, 200 data points per Da; time
domain aggregation method enabled; minimum number of
peaks, 10; precursor charge and m/z, try to re-determine from
the survey scan (tolerance, 2.5 Da); charge defaults, +2/+3;
maximum charge state, +2. iii) Time domain parameters,
minimum precursor mass, 700; maximum precursor mass,
16,000; precursor m/z tolerance for grouping, 0.1; maximum
number of intermediate scans, 5; minimum number of scans in
a group, 1. iv) Peak picking, maximum iterations, 500; correlation threshold, 0.90; minimum signal-to-noise, 3; minimum
peak m/z, 50; maximum peak m/z, 100,000; minimum peak
width, 0.001; maximum peak width, 2; and expected peak
width, 0.01. The resulting Mascot generic files (mgf) were
exported to MASCOT, ver. 2.1.6. The tandem MS data from
the LTQ-FT were searched against National Center for
Biotechnology Information non-redundant databases that were
downloaded on 2008-11-26 with the following constraints:
MS tolerance, 10 ppm, MS/MS tolerance, 0.8 Da with fixed
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Table I. Weights of urinary bladders with OH-BBN induced tumors in female Fischer-344 rats treated with Iressa.
Treatmenta
Iressa, 4.5 mg/kg BW/day
Iressa, 1.5 mg/kg BW/day
None

Urinary bladder + tumors (mg)b	No. of urinary bladder weights >200 mgc
148±9 (55%↓)d
192±14 (42%↓)
332±39		

5/30 (17%)d
10/30 (33%)d
20/29 (69%)

Rats received OH-BBN beginning at 56 days of age. Treatment with Iressa initiated at 115 days of age (i.e., 1 week after the last carcinogen
treatment). bUrinary bladder weights were those observed at sacrifice of the rats (study terminated 8 months after initial OH-BBN treatment).
Values are mean ± SEM (number in parenthesis is percent decrease from controls). cValues represent the number of rats with urinary bladder
weights >200 mg divided by the number of rats in that group. dValues were significantly different (p<0.05) from controls.
a

modifications of cysteine residues (carbamidomethylation)
and variable oxidation of methionine residues. The resulting
DAT files were imported into Scaffold, ver. 2.0 (Proteome
Software, Portland, OR) to identify proteins with >95% confidence and to determine the spectral counts for each protein.
The network analysis was generated using Ingenuity Pathways
Analysis software, ver. 6.
IHC detection of phosporylated proteins. Immunohistochemical detections of phosphorylation of EGFr (Tyr1173),
ERKs, Akt (Ser473), total EGFr and Ki67 were performed.
Bladder tumors were excised and drop fixed in Zamboni's
fixative [0.03% picric acid (w/v) and 2% paraformaldehyde
(w/v)] for 48 h at 5˚C and then transferred to a 20% sucrose
solution with 0.05% sodium azide in PBS for storage at
5˚C. Processing and staining of tumors were carried out
according to a published procedure (13). Whole tumors were
cryosectioned into 80 mm sections. Floating sections were
incubated first with the primary antibody, and then incubated
in 1:10,0000 anti-goat IgG, conjugated to Cy 3 (red color)
or Cy 5 (blue color) (Jackson Immuno Research). Washed
samples were mounted in agar, dehydrated in ethanol, cleared
with methyl salicylate and mounted in DEPEX (Electron
Microscopy Science). Optical sections were captured by laser
scanning confocal microscopy.
RNA isolation and amplification. Bladder tumors were excised
and frozen at -80˚C for subsequent molecular assays. A portion
of each tumor was fixed, processed for paraffin embedding,
cut into 5‑µm sections, and mounted for hematoxylin and
eosin (H&E) staining. All urinary bladder tumors used in
this study were diagnosed as bladder cancers. Total RNA
from bladder tumors treated with Iressa were isolated by
Trizol (Invitrogen, Carlsbad, CA) and purified using the
RNeasy Mini Kit and RNase-free DNase Set (Qiagen,
Valencia, CA) according to the manufacturer's protocol. In vitro
transcription-based RNA amplification was then performed
on each sample. cDNA for each sample was synthesized
using a Superscript cDNA Synthesis Kit (Invitrogen) and a
T7-(dT)24 primer: 5'-GGCCAGTGAATTGTAATACGACT
CACTATAGGGAGGCGG-(dT)24-3'. The cDNA was cleaned
using phase-lock gel phenol/chloroform extraction (Fisher
Scientific). The biotin-labeled cRNA was then transcribed
in vitro from cDNA using a BioArray High Yield RNA

Transcript Labeling Kit (ENZO Biochem, New York, NY) and
purified, again using the RNeasy mini kit.
Affymetrix GeneChip probe array analysis. The labeled
cRNA was applied to the Affymetrix Rat Exon 1.0 ST Array
(Affymetrix, Santa Clara, CA) according to the manufacturer's
recommendations. Gene-level signal estimates for the CEL
files from the platform Rat Exon 1.0 ST Array were derived
by quantile sketch normalization using Iterplier algorithm,
as implemented with Expression Console v1.1.1 (http://
www.affymetrix.com/products services/software/specific/
expressionconsolesoftware.affx). A two-sample student t-test
was used to identify differentially expressed genes (DEGs)
between groups. To adjust for the multiple testing in the study
of high-dimensional microarray data, local false discovery
rate (LFDR) were estimated which was implemented in R
package fdrtool (http://www.r-project.org/) (14). The DEGs
were defined as genes with LFDR <0.05 and fold change >1.5
between two groups.
After identification of DEGs, they are inputted into gene set
enrichment analysis (GSEA). GSEA is a computational method
that determines whether a set of genes shows statistically
significant differences in expression between two biological
states. This has proved successful in discovering molecular
pathways involved in human diseases (http://www.broad.mit.
edu/gsea). Using the Kolmogorov-Smirnov statistic, GSEA
assesses the degree of ‘enrichment’ of a set of genes (e.g., a
pathway) in the entire range of the strength of associations
with the phenotype of interest. It was used to identify a priori
defined sets of genes that were differentially expressed (15,16).
We used curated gene sets (c2) which contain genes in certain
molecular pathways, and GO gene sets (c5) which consist
of genes annotated by the same GO terms in the Molecular
Signature Database (MSigDB, http://www.broad.mit.edu/
gsea/msigdb/msigdb_index.html). Because of small sample
sizes, GSEA with gene set permutation option was performed.
Selected gene sets identified from GSEA were then visualized
with MetaCore™ (http://www.genego.com/). Hierarchical
clustering was performed as follows: For the selected genes,
expression indexes were transformed across samples to an N
(0,1) distribution using a standard statistical Z-transform. These
values were inputted into the GeneCluster program of Eisen
et al (17), and genes were clustered using average linkage and
correlation dissimilarity.
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Results
Effect of Iressa in prevention studies. Iressa was evaluated
at two dose levels to determine the lowest effective dose in
preventing the formation of urinary bladder cancers. Iressa
administered at doses of 4.5 and 1.5 mg/kg BW/day, 7x/week,
decreased the number of large urinary bladder cancers (weights
of total bladder plus tumors >200 mg) from 69% in the controls
to 17 and 33%, respectively (Table I). Furthermore, when the
time of appearance of the palpable urinary bladder tumors
was graphed (Fig. 1A), the 4.5 mg/kg BW/day dose was highly
effective both in increasing tumor latency and in preventing the
development of large tumors. A previous study from our laboratory (1) had demonstrated that a higher dose of Iressa (10 mg/kg
BW/day) was even more effective in preventing the development
of large tumors (Fig. 1B and C). This dose of Iressa was highly
effective in increasing latency and decreasing the incidence
of palpable tumors when administered beginning 1 week or 3
months after the last dose of OH-BBN. The efficacy seen in
the late administration is particularly interesting because at
the later point 70% of rats already had invasive carcinomas
(Fig. 1C).
Effects of EGFr inhibitors on tumor related biomarkers. Based
on the striking efficacy following late administration of Iressa, we
examined the effects of limited treatment for 5 days on palpable
bladder cancers with Iressa (10 mg/kg BW/day). Three different
approaches were employed to identify potential biomarkers.
Examination of EGFr pathway related biomarkers (Fig. 2).
The primary focus of these studies was to examine the effect
of Iressa on proteins associated with the EGFr pathway
including EGFr and its downstream effector proteins AKT and
ERK. Using immunohistochemistry and confocal microscopy,
it was found that levels of phosphorylated EGFr (Tyr1173), Akt
(Ser473) and ERKs were decreased by 50, 75 and 47%, respectively, in bladder cancers from rats receiving Iressa. These
differences were found to be significant, and demonstrate the
direct effects of Iressa on the EGFr pathway.
Examination of the effects of Iressa on protein expression
employing 2D gel (Fig. 3). In these studies, protein expression
levels from Iressa treated and control tumors were measured by
labeling with fluorometrically distinct cyanine dyes (18). In the
image shown in Fig. 3A, the green colored gel features indicate
proteins that are decreased in the treated samples. Of the 1500
gel features, roughly 200 were found to be changed outside of
the 95% confidence percentile. The differential gel features
were excised, digested with trypsin in situ, and the proteins
identified from the fragmentation spectra of the peptides.
A three dimensional view of two proteins associated with
the VEGF pathway [Annexin A2 and MAP kinase kinase
(MAP2K)] were shown to be decreased 2.3- and 4.5-fold,
respectively, in the tumors from treated rats. The complete set
of differentially expressed proteins was analyzed for network
and pathway associations using Ingenuity Pathways Analysis.
The VEGF pathway exhibited decreases in Annexin A2 and
MAP kinase kinase (Fig. 3B), but also showed decreases in
nucleolin (NCL) and the small GTPase Rho A; both of which
also function in the VEGF pathway.

Figure 1. Effects of Iressa on the time of appearance of palpable urinary
bladder tumors in female Fischer-344 rats. (A) Iressa (4.5 and 1.5 mg/kg BW/
day) was administered from one week after the final OH-BBN treatment until
the end of the study. ○, Iressa 4.5 mg/kg BW/day; ◻, Iressa 1.5 mg/kg BW/
day; ●, control. (B) Effects of high dose Iressa (10 mg/kg BW/day) on time
of appearance of palpable urinary bladder tumors in female Fischer-344 rats
(1). Iressa was started one week after the final OH-BBN treatment. ○, Iressa
10 mg/kg BW/day; ●, control (C). Iressa was started 3 months after the final
OH-BBN treatment. ○, Iressa 10 mg/kg BW/day; ●, control.

Examination of the effects of Iressa on gene expression
employing oligonucleotide microarrays (Figs. 4 and 5). In
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all substantially decreased in Iressa treated vs control bladder
tumors. When expression of the genes coding for E cadherin
and vimentin were compared in normal bladder epithelium
and bladder tumors, Cdh1 was modestly down-regulated in
bladder tumors (LFDR=0.003 and fold change = -1.42); no
difference in expression of Vim was found.
Discussion

Figure 2. Immunostaining and quantitation of pEGFR, total EGFR, pAKT and
pERKs in urinary bladder tumors from untreated or Iressa treated rats (10 mg/kg
BW/day for 5 days). (A) Representative bladder cancers from untreated rats (left
3 columns) or Iressa treated rats (right 3 columns). Slides were immunolabeled
with antibodies to detect specific proteins (top row, pEGFR; second from top,
EGFR; third from top, pAKT; bottom, pERK). The image is a z-projection
created from 30 1 µ sections using laser confocal microscopy (Nikon Clsi
Confocal Spectral Imaging System, Nikon Instrument Company) with a CFI
Plan Fluorx 20x objective. (B) The light intensity of three different cancers
was estimated using the Image J computer program; data shown as mean ± SD.
Asterisk indicates decreased expression, P<0.05.

these studies, the effects of Iressa on gene expression by
employing oligonucleotide microarrays were determined.
As shown in Fig. 5, there were an extremely large number
of genes whose expressions were altered when comparing
bladder cancers treated short-term with Iressa and control
bladder cancers. The resulting gene expression changes
were examined using gene pathway analysis, and genes
in several pathways were identified. The gene expression
pathway analysis (Fig. 4) and accompanying expression
levels (Table II) of genes associated with cell cycle pathways
[specifically, the anaphase protein complex (APC)] are
presented. Expression of various genes, including cyclins B
and D, CDC20, BUBR1, BUB1, securin and Aurora B, were

Studies were performed to examine the efficacy of an EGFr
inhibitor in the OH-BBN induced model of urinary bladder
cancers, as well as to examine potential expression changes
which might prove applicable as pharmacodynamic or efficacy biomarkers in clinical trials using this class of agents.
The tumors that develop in the OH-BBN induced model are
primarily transitional cell or mixed cell carcinomas as defined
by histopathology. In addition, they exhibit many changes
found in human bladder cancers (3,4), including increased
levels of survivin, GST Pi, Annexin, various S-100 proteins,
and decreased levels of FHIT. Recently, we have compared
urinary bladder tumors with normal bladder epithelium
employing gene arrays (4). Those results showed alterations in
a variety of pathways including general overexpression of the
genes related to the EGFr pathway.
Based on the fact that EGFr is expressed at higher levels
in bladder tumors than in normal bladder epithelium (6,7),
both in humans and in rats, the efficacy of Iressa was tested in
the OH-BBN bladder cancer model. Iressa treatment initiated
at one week following the last dose of OH-BBN yielded a
dose-dependent decrease in the formation of urinary bladder
cancers. Interestingly, the highest dose employed (10 mg/kg
BW/day) is approximately 2x less than the typical human dose;
based on a standard rat/human scaling factor (1). It was found
that even lower doses of Iressa (4.5 and 1.5 mg/kg BW/day)
were effective in preventing OH-BBN induced bladder tumors.
More importantly, the highest dose of Iressa was highly effective in increasing tumor latency when administered beginning
three months following the final dose of OH-BBN (Fig. 1C); at a
time when 70% of animals had already developed microscopic
invasive bladder lesions (1). Highly significant prevention at
this late stage suggests that the effect of Iressa was primarily
on the progression stage of the carcinogenic process. Based on
these findings, various data with human bladder cancer cell
cultures, and the finding that EGFr is overexpressed in many
human bladder cancers support the use of an EGFr inhibitor
in an adjuvant setting in humans. In fact, the EGFr inhibitors
Tarceva (EGFr1) and Lapatinib (EGFr 1 and 2) have undergone
small Phase II trials in more advanced bladder cancers, and
both appear to show activity (19,20).
The determination of potential biomarkers has multiple
objectives. First, it may offer some mechanistic insights into
the mode of action of a given agent or class of agents. Although
in the case of Iressa, the primary target is clearly defined.
Changes in specific pathways [e.g., VEGF (proteomics) or
cell cycle (genomics)], may give insights into the molecular
mechanism(s) underlying the efficacy of the agent. Second,
since these changes are observed at a highly effective dose of
Iressa, some of the observed changes may identify biomarkers
related to the efficacy of the agent. However, even if these
changes are primarily pharmacodynamic (implying pharma-
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Figure 3. Proteomic analysis of urinary bladder cancers from Iressa-treated and control rats. (A) Two-dimensional difference gel electrophoresis as described
in Materials and methods. Green spots are overexpressed in control tumors. Red spots are overexpressed in Iressa-treated tumors. (B) Topological mapping of
two individual spots (Annexin A2, MAP2K1) after identification of peptides by mass spectrometry.

Figure 4. Effects of Iressa on cell cycle related genes associated with anaphase promoting complex (APC). Alterations in specific genes are based on
Affymatrix analysis of gene expression (Materials and methods).
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Figure 5. Gene showing changes in expression when comparing cancers from Iressa-treated and control rats. Data based on microarray analysis: red, overexpressed; green, underexpressed; black, average expression.

Table II. Significant changes in gene expression in cell cyle APC related pathway.
Mean ± SD
--------------------------------------------------------------------Probe set ID	Gene	Control tumor	Treated tumor	P-value	LFDR	
7290458	Cdc20
7207681	Ccna2
7203074	Ccnb1
7036458	Plk1
7244612
Bub1
7231515
Bub1b
7076550	Pttg1
7057437
Kif22
7248426
Aurka
7068974
Aurkb
7258359	Cdca3
7218195	Cdc2

372±113
522±194
425±124
691±253
498±161
359±128
207±77
278±84
255±66
352±131
225±63
224±59

124±70
198±162
162±121
249±177
205±156
137±86
81±55
125±75
155±56
132±99
86±34
110±74

0.000116
0.002608
0.000569
0.001245
0.002007
0.00118
0.002172
0.001485
0.005007
0.001997
9.24E-05
0.003072

0.0056
0.019895
0.009926
0.012326
0.015968
0.012326
0.015968
0.012708
0.027147
0.015968
0.004977
0.020887

Fold change
3.01
2.64
2.62
2.77
2.43
2.63
2.55
2.23
1.65
2.66
2.63
2.03

1396

Lubet et al: Iressa and Urinary Bladder Cancer

cologic/physiologic effects) for the agent, these biomarkers
may be important to potential clinical prevention trials,
particularly Phase II trials. In examining the biomarker
data, one must be aware that although Iressa can block
further tumor development (even beginning at a time when
established carcinomas exist), it has not been shown that it
can cause the regression of existing large lesions. Part of the
problem is that we typically identify palpable lesions that are
relatively large and that have invaded the underlying tissues.
Thus, a method should be developed that will permit the
identification of smaller lesions in order to determine whether
an EGFr inhibitor is therapeutic in this model.
The first set of potential biomarkers examined was
directly related to inhibition of phosphorylated EGFr.
Immunohistochemistry showed that Iressa induced significant
decreases in amounts of phosphorylated EGFr (Tyr 1173)s,
phosphorylated AKT (ser 473) and phosphorylated ERKs.
Interestingly, our laboratories have observed modulation of
these same parameters in a mammary cancer model in which
Iressa was similarly highly effective. In this case, the results
were confirmed employing Western blot analyses. These studies
parallel a pre-surgical model of cancer that could demonstrate
the modulation of the expected targets of the inhibitor (8).
The second biomarker approach looked at potential
changes in expression of various proteins of bladder cancers
employing a 2D gel approach. Proteins were extracted,
labeled with cyanine dyes, separated by 2D electrophoresis,
and the images were co-registered with software. The relative
abundance of proteins in tumors of Iressa-treated rats can
be determined without variability associated with aligning
images from multiple 2D analyses. The verification of the
approach is illustrated by the identification of proteins that are
well recognized to be associated with the effects of the VEGF
pathway in tumor angiogenesis (Fig. 3). Annexin II is a tumor
associated protein with a potential role in tumor progression
and angiogenesis (21). The decrease in expression of MAPK
kinase, a protein associated with angiogeneis (22), suggests
downstream effects of EGFr inhibitors. In summary, these 2D
gel findings are consistent with previous data indicating that
alterations in the VEGF pathway are associated with effects
of the EGFr inhibitors (23). These changes, as mentioned
above, are probably secondary to the initial inhibition of
EGFr phosphorylation. Nevertheless, changes in the angiogenesis pathway may contribute to the overall efficacy that
was observed.
Finally, gene expression oligonucleotide arrays were
performed to determine which genes exhibit altered expression levels in bladder cancers from Iressa treated rats.
Although gene expression is two steps removed from protein
function and protein expression, it has many advantages;
including the ability to examine simultaneously the widest
variety of genes, and to integrate the results into pathways
or functional analyses. Numerous pathways were found to
be altered (cell cycle, G-protein receptor, DNA damage and
DNA repair). The genes associated with the anaphase protein
complex pathway that were altered are presented in Table II
and Fig. 4. The changes were statistically significant and
caused 2- to 4-fold decreases in gene expression. Included
among these genes were ccna2, cdc2, cdc20, cyclin
B1 and Aurora kinases A and B. These differences support

the finding of substantial decreases in proliferation in Iressatreated vs control bladder cancers (data not shown). The
changes also correlate with the high efficacy of Iressa in this
model of urinary bladder cancer (Fig. 1A and B). We also
examined the expression of E  cadherin (an epithelial cell
marker) and vimentin (a mesenchymal cell marker) in normal
urinary bladder epithelium and bladder cancers. The rationale
being that tumors which have undergone a mesenchymal cell
transition are less likely to respond to an EGFr inhibitor. The
minimal differences observed in expression of E cadherin and
vimentin likely reflect a limited mesenchymal transition and
may suggest that EGFr inhibitors are highly effective; even
at the later stages of progression. We feel that these potential
biomarkers may be useful in clinical prevention or in adjuvant
trials with this class of agents. One would not expect that
most or all of the biomarkers from a rat would translate into a
human, although the biomarkers directly related to the EGFr
phosphorylation pathway (EGFrP, AktP and ERKP) are likely
to be relevant across species. Furthermore, more complete
analyses of the results from the 2D gels and gene arrays may
yield a wide variety of potential biomarkers, of which some
significant number are likely to be relevant to humans.
Acknowledgements
The authors wish to thank Jeanne Hale and Mary Jo Cagle
for secretarial and editorial services. Also, thanks are
expressed to Tom Morgan, Bonnie Dillion, Emily Meadows,
John Houston and Jimmy Anderson for assistance with the
animal studies.
References
1.	Lubet RA, Steele VE, Juliana MM and Grubbs CJ: Screening
agents for preventive efficacy in a bladder cancer model: study
design, endpoints, and gefitinib and naproxen efficacy. J Urol
183: 1598‑1603, 2010.
2.	Lubet RA, Yang CS, Lee MJ, et al: Preventive effects of polyphenone E on urinary bladder and mammary cancers in rats and
correlations with serum and urine levels of tea polyphenols. Mol
Cancer Ther 6: 2022-2028, 2007.
3.	Lubet RA, Huebner K, Fong LY, et al: 4-Hydroxybutyl(butyl)
nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive
effects of indomethacin. Carcinogenesis 26: 571‑578, 2005.
4.	Yao R, Yi Y, Grubbs CJ, Lubet RA and You M: Gene expression
profiling of chemically induced rat bladder tumors. Neoplasia 9:
207‑221, 2007.
5. Williams PD, Lee JK and Theodorescu D: Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 8:
838‑846, 2008.
6.	Chow NH, Chan SH, Tzai TS, Ho CL and Liu HS: Expression
profiles of ErbB family receptors and prognosis in primary
transitional cell carcinoma of the urinary bladder. Clin Cancer
Res 7: 1957-1962, 2001.
7.	Colquhon AJ and Mellon JK: Epidermal growth factor receptor
and bladder cancer. Postgrad Med J 78: 584-589, 2002.
8. Baselga J: Targeting the epidermal growth factor receptor: a
clinical reality. J Clin Oncol 10: 41-45, 2001.
9.	Steele VE, Rao CV, Zhang Y, et al: Chemopreventive efficacy of
naproxen and nitric oxide-naproxen in rodent models of colon,
urinary bladder, and mammary cancers. Cancer Prev Res 2:
951‑956, 2009.
10. Alban A, David SO, Bjorkesten L, Anderson C, Sloge E,
Lewis C and Currie I: A novel experimental design for comparative two-dimensional gel analysis: two dimensional difference
gel electrophoresis incorporating a pooled internal standard.
Proteomic 3: 36-44, 2003.

oncology reports 25: 1389-1397, 2011

11. Bredemeyer AJ, Lewis RM, Malone JD, Davis AE, Gross J,
Townsend RR and Ley TJ: A proteomic approach for the
discovery of protease substrates. Proc Natl Acad Sci USA 101:
11785‑11790, 2004.
12. King JB, Gross J, Lovly CM, Rohrs H, Piwnics-Worms H and
Townsend RR: Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2
protein kinase. Anal Chem 78: 2171-2181, 2006.
13. Wacnik PW, Baker CM, Herron MJ, et al: Tumor-induced
mechanical hyperalgesia involves CGRP receptors and altered
innervation and vascularization of DsRed2 fluorescent hindpaw
tumors. Pain 115: 95-106, 2005.
14. Strimmer K: A unified approach to false discovery rate estimation. BMC Bioinformatics 9: 303, 2008.
15. Mootha VK, Lindgren CM, Eriksson KF, et al: PGC-1alpharesponsive genes involved in oxidative phosphorylation are
coordinately down-regulated in human diabetes. Nat Genet 34:
267‑273, 2003.
16.	Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci USA 102:
15545‑15550, 2005.

1397

17.	Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster
analysis and display of genome-wide expression patterns. Proc
Natl Acad Sci USA 95: 14863-14868, 1998.
18. Unlu M, Morgan ME and Minden JS: Difference gel electrophoresis: a single gel method for detecting changes in protein
extracts. Electrophoresis 18: 2071-2077, 2005.
19. Wulfing C, Machiels JP, Richel DJ, et al: A single arm, multicenter, open-label phase 2 study of lapatinib as the second
line treatment of patients with locally advanced or metastatic
transitional cell carcinoma. Cancer 115: 2881-2890, 2009.
20.	Pruthi RS, Nielson M, Heathcote S, et al: A phase II trial of
neoadjuvant erlotinib in patients with muscle-invasive bladder
cancer undergoing radical cystectomy: clinical and pathological
results. BJU Inter 106: 349-356, 2010.
21.	Sharma MC and Sharma M: The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Current Pharm Design 13: 3568-3575, 2007.
22. Kim LC, Song L and Harua EB: Src kinases as therapeutic
targets for cancer. Nat Rev Clin Oncol 6: 587-595, 2009.
23. Kassouf W, Brown GA and Black PC: Is vascular endothelial
growth factor modulation a predictor of the therapeutic efficacy
of gefitinib for bladder cancer? J Urol 180: 1146‑1153, 2008.

